Company
Acceleron Pharma Inc.
Headquarters: Cambridge, MA, United States
Founded: 2003
Employees: 225
Market Cap
$10.56 Billion
USD as of Nov. 1, 2021
Acceleron Pharma Inc. Categories
United States Healthcare BiotechnologyUnited States Healthcare United States Biotechnology
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $622.07 B |
| Vertex Pharmaceuticals Incorporated | $113.24 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $76.33 B |
| Marinomed Biotech AG | $56.13 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Detailed Description
Acceleron Pharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. It offers luspatercept-aamt for the treatment of anemia in adult patients with beta-thalassemia under the REBLOZYL name. The company also develops luspatercept-aamt for the treatment of myelodysplastic syndromes and myelofibrosis; Sotatercept for the treatment of patients with pulmonary arterial hypertension; and ACE-083, a neuromuscular candidate that is in Phase II clinical trials for the treatment of patients with Charcot-Marie-Tooth disease. In addition, it has a collaboration, license, and option agreement with Celgene Corporation; and collaboration and license agreement with Fulcrum Therapeutics, Inc. to identify small molecules designed to modulate specific pathways associated with a targeted indication within the pulmonary disease space. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.
Financials
| Last Financial Reports Date | Sept. 30, 2021 |
| Revenue TTM | $92.5 M |
| EBITDA | $None |
| Gross Profit TTM | $-81,394,000 |
| Profit Margin | % |
| Operating Margin | % |
| Quarterly Revenue Growth | 22.40% |
Stocks & Indices
Acceleron Pharma Inc. has the following listings and related stock indices.
Stock: NASDAQ: XLRN wb_incandescent
Stock: FSX: 0A3 wb_incandescent
Key People
Habib Dable (CEO) Steve Ertel (COO) Matt Sherman (CMO) Kevin Mc Laughlin (CFO) Francois Nader (Chairman)